199 related articles for article (PubMed ID: 10447756)
1. The influence of complement receptor type 1 (CD35) and decay-accelerating factor (CD55) on complement receptor type 2- (CD21) mediated alternative pathway activation by B cells.
Leslie RG
Immunology; 1999 Jul; 97(3):371-3. PubMed ID: 10447756
[TBL] [Abstract][Full Text] [Related]
2. The role of complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) in promoting C3 fragment deposition and membrane attack complex formation on normal peripheral human B cells.
Nielsen CH; Pedersen ML; Marquart HV; Prodinger WM; Leslie RG
Eur J Immunol; 2002 May; 32(5):1359-67. PubMed ID: 11981823
[TBL] [Abstract][Full Text] [Related]
3. The requirement of localized, CR2-mediated, alternative pathway activation of complement for covalent deposition of C3 fragments on normal B cells.
Olesen EH; Johnson AA; Damgaard G; Leslie RG
Immunology; 1998 Feb; 93(2):177-83. PubMed ID: 9616366
[TBL] [Abstract][Full Text] [Related]
4. Two modes of homologous C3 deposition on Ramos Burkitt's lymphoma cell substrains co-expressing DAF (CD55), CD59, and CR2 (CD21), and on cells lacking them.
Seya T; Hara T; Okada M; Kojima A; Matsumoto M; Akedo H
Int Immunol; 1992 Dec; 4(12):1361-71. PubMed ID: 1283697
[TBL] [Abstract][Full Text] [Related]
5. CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytes.
Nielsen CH; Marquart HV; Prodinger WM; Leslie RG
Immunology; 2001 Dec; 104(4):418-22. PubMed ID: 11899427
[TBL] [Abstract][Full Text] [Related]
6. Complement alternative pathway activation and control on membranes of human lymphoid B cell lines.
Caudwell V; Porteu F; Calender A; Pangburn MK; Halbwachs-Mecarelli L
Eur J Immunol; 1990 Dec; 20(12):2643-50. PubMed ID: 1702720
[TBL] [Abstract][Full Text] [Related]
7. Complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) cooperate in the binding of hydrolyzed complement factor 3 (C3i) to human B lymphocytes.
Leslie RG; Prodinger WM; Nielsen CH
Eur J Immunol; 2003 Dec; 33(12):3311-21. PubMed ID: 14635039
[TBL] [Abstract][Full Text] [Related]
8. Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells.
Kozono Y; Abe R; Kozono H; Kelly RG; Azuma T; Holers VM
J Immunol; 1998 Feb; 160(4):1565-72. PubMed ID: 9469411
[TBL] [Abstract][Full Text] [Related]
9. Complement-activating ability of leucocytes from patients with complement factor I deficiency.
Marquart HV; Rasmussen JM; Leslie RG
Immunology; 1997 Jul; 91(3):486-92. PubMed ID: 9301541
[TBL] [Abstract][Full Text] [Related]
10. Complement activation by malignant B cells from patients with chronic lymphocytic leukaemia (CLL).
Marquart HV; Grønbaek K; Christensen BE; Svehag SE; Leslie RG
Clin Exp Immunol; 1995 Dec; 102(3):575-81. PubMed ID: 8536375
[TBL] [Abstract][Full Text] [Related]
11. Co-operation between human CR1 (CD35) and CR2 (CD21) in internalization of their C3b and iC3b ligands by murine-transfected fibroblasts.
Grattone ML; Villiers CL; Villiers MB; Drouet C; Marche PN
Immunology; 1999 Sep; 98(1):152-7. PubMed ID: 10469246
[TBL] [Abstract][Full Text] [Related]
12. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells.
Schwendinger MG; Spruth M; Schoch J; Dierich MP; Prodinger WM
J Immunol; 1997 Jun; 158(11):5455-63. PubMed ID: 9164968
[TBL] [Abstract][Full Text] [Related]
13. CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes.
Marquart HV; Svehag SE; Leslie RG
J Immunol; 1994 Jul; 153(1):307-15. PubMed ID: 7515925
[TBL] [Abstract][Full Text] [Related]
14. Human complement regulatory proteins expressed on mouse A9 cells containing a human chromosome 1.
Seya T; Okada M; Hara T; Matsumoto M; Miyagawa S; Oshimura M
Immunology; 1991 Dec; 74(4):719-24. PubMed ID: 1723716
[TBL] [Abstract][Full Text] [Related]
15. Complement receptor type 1 (CR1, CD35) is a potent inhibitor of B-cell functions in rheumatoid arthritis patients.
Kremlitzka M; Polgár A; Fülöp L; Kiss E; Poór G; Erdei A
Int Immunol; 2013 Jan; 25(1):25-33. PubMed ID: 22962438
[TBL] [Abstract][Full Text] [Related]
16. Detection of complement receptors 1 and 2 on mouse splenic B cells using flow cytometry.
Donius LR; Weis JH
Methods Mol Biol; 2014; 1100():305-10. PubMed ID: 24218269
[TBL] [Abstract][Full Text] [Related]
17. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis.
Kuraya M; Yefenof E; Klein G; Klein E
Eur J Immunol; 1992 Jul; 22(7):1871-6. PubMed ID: 1378022
[TBL] [Abstract][Full Text] [Related]
18. Expression and role of CR1 and CR2 on B and T lymphocytes under physiological and autoimmune conditions.
Erdei A; Isaák A; Török K; Sándor N; Kremlitzka M; Prechl J; Bajtay Z
Mol Immunol; 2009 Sep; 46(14):2767-73. PubMed ID: 19559484
[TBL] [Abstract][Full Text] [Related]
19. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21).
Ahearn JM; Fearon DT
Adv Immunol; 1989; 46():183-219. PubMed ID: 2551147
[No Abstract] [Full Text] [Related]
20. Evidence for the role of CR1 (CD35), in addition to CR2 (CD21), in facilitating infection of human T cells with opsonized HIV.
Delibrias CC; Kazatchkine MD; Fischer E
Scand J Immunol; 1993 Aug; 38(2):183-9. PubMed ID: 8346417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
